Wire · opportunities
FDA clears C2N Diagnostics' first blood test for early Alzheimer's
◆ Sectors
Digital Health
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 11 September 2026 · Fusion42 review
The FDA has cleared C2N Diagnostics' PrecivityAD2 blood test for early detection of Alzheimer’s in symptomatic adults aged 40 and older, enabling a less invasive and more accessible diagnostic alternative to PET scans and spinal taps.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
You can now bring early Alzheimer’s testing to symptomatic younger adults with a simple blood draw, avoiding costly scans and painful spinal taps. This clears the way for quicker patient diagnosis and earlier treatment starts that are critical for effective therapy.
◆ Coverage
1 source · 11 Sep 2026
◆ Related on Wire
◆ Topics
Digital Healthalzheimersdiagnosticsblood-testFDA-clearancedigital-healthlongevity